Actinogen Medical Limited (ATGGF)
OTCMKTS
· Delayed Price · Currency is USD
0.0200
0.00 (0.00%)
Dec 24, 2024, 4:00 PM EST
Actinogen Medical Company Description
Actinogen Medical Limited, a biotechnology company, develops therapies for neurological and neuropsychiatric diseases associated with dysregulated brain cortisol in Australia.
It develops Xanamem, an oral medication and inhibitor of the 11β-HSD1 enzyme, which is in Phase 2 clinical trials, that achieves target engagement in the brain for the treatment of Alzheimer’s disease, major depressive disorder, fragile x syndrome, and other neurological diseases.
The company was formerly known as Actinogen Limited and changed its name to Actinogen Medical Limited in November 2015.
Actinogen Medical Limited was incorporated in 1999 and is based in Sydney, Australia.
Actinogen Medical Limited
| Country | Australia |
| Founded | 1999 |
| Industry | Biotechnology |
| Sector | Healthcare |
| Employees | 6 |
| CEO | Steven Gourlay |
Contact Details
Address: 109 Pitt Street Sydney, 2000 Australia | |
| Phone | 61 2 8964 7401 |
| Website | actinogen.com.au |
Stock Details
| Ticker Symbol | ATGGF |
| Exchange | OTCMKTS |
| Fiscal Year | July - June |
| Reporting Currency | AUD |
| ISIN Number | AU000000ACW3 |
| SIC Code | 2836 |
Key Executives
| Name | Position |
|---|---|
| Dr. Steven G. Gourlay ), FRACP, M.B.A., MBBS (M.D., Ph.D. | MD, Chief Executive Officer and Director |
| William Edward Souter BCom, IPAA, LLB (Adel) | Chief Financial Officer |
| Dr. Dana C. Hilt M.D. | Chief Medical Officer and Member of Depression and Cognition Clinical Advisory Board |
| Michael Roberts | Head of Investor Relations and Corporate Communications |
| Prof. Paul Rolan D.C.P.S.A., F.F.P.M., F.R.A.C.P., M.B.B.S., M.D. | Head of Clinical Pharmacology and Lead Physician and Depression |
| Dr. Fujun Li Ph.D. | Head of Manufacturing |
| Andrew B. Udell B.Sc., M.B.A. | Chief Commercial Officer |
| Peter Gordon Webse B.Bus, FCIS, FCPA, FGIA, M.A.I.C.D. | Company Secretary |